Pharma Sector Q3 Earnings Preview - Moderate Ebitda Growth: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
We expect pharmaceuticals companies under our coverage to report moderate Ebitda growth of 3% YoY (flat QoQ) led by-
lack of meaningful approvals in U.S. and
higher cost of goods sold.
Our pharma universe’s domestic business will continue to see strong traction in the quarter, growing in double-digits YoY and U.S. business may remain steady QoQ. Cost pressure to remain elevated with higher freight and cost of goods sold on YoY basis, however QoQ should be stable.
Indian rupee depreciation against U.S. dollar is marginal on QoQ and YoY basis, while appreciated again Brazilian real and euro.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.